Format
Sort by
Items per page

Send to

Choose Destination

Search Tip

Sort by Best Match to display results from highest to lowest relevance to your search terms.

Try it Now

Search results

Items: 1 to 20 of 161

1.

Matrix-regulated integrin αvβ5 maintains α5β1-dependent desmoplastic traits prognostic of neoplastic recurrence.

Franco-Barraza J, Francescone R, Luong T, Shah N, Madhani R, Cukierman G, Dulaimi E, Devarajan K, Egleston BL, Nicolas E, Katherine Alpaugh R, Malik R, Uzzo RG, Hoffman JP, Golemis EA, Cukierman E.

Elife. 2017 Jan 31;6. pii: e20600. doi: 10.7554/eLife.20600.

2.

Is It Time for Total Neoadjuvant Therapy for Patients With Resectable Pancreatic Adenocarcinoma?

Hoffman JP, Reddy SS.

J Oncol Pract. 2016 Sep;12(9):780-1. doi: 10.1200/JOP.2016.016352. No abstract available.

PMID:
27621327
3.

Screening of Conditionally Reprogrammed Patient-Derived Carcinoma Cells Identifies ERCC3-MYC Interactions as a Target in Pancreatic Cancer.

Beglyarova N, Banina E, Zhou Y, Mukhamadeeva R, Andrianov G, Bobrov E, Lysenko E, Skobeleva N, Gabitova L, Restifo D, Pressman M, Serebriiskii IG, Hoffman JP, Paz K, Behrens D, Khazak V, Jablonski SA, Golemis EA, Weiner LM, Astsaturov I.

Clin Cancer Res. 2016 Dec 15;22(24):6153-6163. Epub 2016 Jul 6.

PMID:
27384421
4.

Preoperative Modified FOLFIRINOX Treatment Followed by Capecitabine-Based Chemoradiation for Borderline Resectable Pancreatic Cancer: Alliance for Clinical Trials in Oncology Trial A021101.

Katz MH, Shi Q, Ahmad SA, Herman JM, Marsh Rde W, Collisson E, Schwartz L, Frankel W, Martin R, Conway W, Truty M, Kindler H, Lowy AM, Bekaii-Saab T, Philip P, Talamonti M, Cardin D, LoConte N, Shen P, Hoffman JP, Venook AP.

JAMA Surg. 2016 Aug 17;151(8):e161137. doi: 10.1001/jamasurg.2016.1137. Epub 2016 Aug 17.

5.

Dosimetric predictors of hematologic toxicity in patients undergoing concurrent gemcitabine-based chemoradiation for localized pancreatic cancer.

Shaikh T, Wang LS, Egleston B, Burki M, Hoffman JP, Cohen SJ, Meyer JE.

Pract Radiat Oncol. 2016 Jul-Aug;6(4):e107-15. doi: 10.1016/j.prro.2015.11.005. Epub 2015 Nov 14.

PMID:
27032572
6.

RECQ1 A159C Polymorphism Is Associated With Overall Survival of Patients With Resected Pancreatic Cancer: A Replication Study in NRG Oncology Radiation Therapy Oncology Group 9704.

Li D, Moughan J, Crane C, Hoffman JP, Regine WF, Abrams RA, Safran H, Liu C, Chang P, Freedman GM, Winter KA, Guha C, Abbruzzese JL.

Int J Radiat Oncol Biol Phys. 2016 Mar 1;94(3):554-60. doi: 10.1016/j.ijrobp.2015.10.062. Epub 2015 Nov 5.

7.

Predictors of Hematologic Toxicity and Chemotherapy Dose Intensity in Patients Undergoing Chemoradiation for Pancreatic Cancer.

Shaikh T, Wang LS, Egleston B, Burki M, Hoffman JP, Cohen SJ, Meyer JE.

Am J Clin Oncol. 2015 Aug 28. [Epub ahead of print]

8.

Management of the Primary Tumor and Limited Metastases in Patients With Metastatic Pancreatic Cancer.

Herman JM, Hoffman JP, Thayer SP, Wolff RA.

J Natl Compr Canc Netw. 2015 May;13(5):e29-36. Review.

PMID:
26158133
9.

Dose escalation with a vessel boost in pancreatic adenocarcinoma treated with neoadjuvant chemoradiation.

Wang LS, Shaikh T, Handorf EA, Hoffman JP, Cohen SJ, Meyer JE.

Pract Radiat Oncol. 2015 Sep-Oct;5(5):e457-63. doi: 10.1016/j.prro.2015.04.004. Epub 2015 Jun 12.

10.

Bilateral granulosa cell tumors: a novel malignant manifestation of multiple endocrine neoplasia 1 syndrome found in a patient with a rare menin in-frame deletion.

Hall MJ, Innocent J, Rybak C, Veloski C, Scott WJ, Wu H, Ridge JA, Hoffman JP, Borghaei H, Turaka A, Daly MB.

Appl Clin Genet. 2015 Feb 17;8:69-73. doi: 10.2147/TACG.S72223. eCollection 2015.

11.

Morbidity among long-term survivors after pancreatoduodenectomy for pancreatic adenocarcinoma.

Chen KT, Devarajan K, Hoffman JP.

Ann Surg Oncol. 2015 Apr;22(4):1185-9. doi: 10.1245/s10434-014-3969-y. Epub 2014 Nov 11.

PMID:
25384699
12.

Pancreatic adenocarcinoma, version 2.2014: featured updates to the NCCN guidelines.

Tempero MA, Malafa MP, Behrman SW, Benson AB 3rd, Casper ES, Chiorean EG, Chung V, Cohen SJ, Czito B, Engebretson A, Feng M, Hawkins WG, Herman J, Hoffman JP, Ko A, Komanduri S, Koong A, Lowy AM, Ma WW, Merchant NB, Mulvihill SJ, Muscarella P 2nd, Nakakura EK, Obando J, Pitman MB, Reddy S, Sasson AR, Thayer SP, Weekes CD, Wolff RA, Wolpin BM, Burns JL, Freedman-Cass DA.

J Natl Compr Canc Netw. 2014 Aug;12(8):1083-93.

PMID:
25099441
13.
14.

Potential prognostic biomarkers of pancreatic cancer.

Chen KT, Kim PD, Jones KA, Devarajan K, Patel BB, Hoffman JP, Ehya H, Huang M, Watson JC, Tokar JL, Yeung AT.

Pancreas. 2014 Jan;43(1):22-7. doi: 10.1097/MPA.0b013e3182a6867e.

15.

Neoadjuvant chemoradiation and duration of chemotherapy before surgical resection for pancreatic cancer: does time interval between radiotherapy and surgery matter?

Chen KT, Devarajan K, Milestone BN, Cooper HS, Denlinger C, Cohen SJ, Meyer JE, Hoffman JP.

Ann Surg Oncol. 2014 Feb;21(2):662-9. doi: 10.1245/s10434-013-3396-5. Epub 2013 Nov 26.

PMID:
24276638
16.

An iPSC line from human pancreatic ductal adenocarcinoma undergoes early to invasive stages of pancreatic cancer progression.

Kim J, Hoffman JP, Alpaugh RK, Rhim AD, Reichert M, Stanger BZ, Furth EE, Sepulveda AR, Yuan CX, Won KJ, Donahue G, Sands J, Gumbs AA, Zaret KS.

Cell Rep. 2013 Jun 27;3(6):2088-99. doi: 10.1016/j.celrep.2013.05.036. Epub 2013 Jun 20. Erratum in: Cell Rep. 2013 Jul 25;4(2):403. Rhimm, Andrew D [corrected to Rhim, Andrew D].

17.

Partial stomach-partitioning gastrojejunostomy and the success of this procedure in terms of palliation.

Arrangoiz R, Papavasiliou P, Singla S, Siripurapu V, Li T, Watson JC, Hoffman JP, Farma JM.

Am J Surg. 2013 Sep;206(3):333-9. doi: 10.1016/j.amjsurg.2012.11.015. Epub 2013 May 22.

PMID:
23706260
18.

How to define and manage borderline resectable pancreatic cancer.

Papavasiliou P, Chun YS, Hoffman JP.

Surg Clin North Am. 2013 Jun;93(3):663-74. doi: 10.1016/j.suc.2013.02.005. Epub 2013 Mar 27. Review.

PMID:
23632151
19.

Impact of preoperative therapy on patterns of recurrence in pancreatic cancer.

Papavasiliou P, Hoffman JP, Cohen SJ, Meyer JE, Watson JC, Chun YS.

HPB (Oxford). 2014 Jan;16(1):34-9. doi: 10.1111/hpb.12058. Epub 2013 Feb 20.

20.

Weekly paclitaxel, gemcitabine, and external irradiation followed by randomized farnesyl transferase inhibitor R115777 for locally advanced pancreatic cancer.

Rich TA, Winter K, Safran H, Hoffman JP, Erickson B, Anne PR, Myerson RJ, Cline-Burkhardt VJ, Perez K, Willett C.

Onco Targets Ther. 2012;5:161-70. doi: 10.2147/OTT.S33560. Epub 2012 Aug 23.

Supplemental Content

Loading ...
Support Center